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Prehospital transdermal glyceryl trinitrate in patients with 
ultra-acute presumed stroke (RIGHT-2): an ambulance-based, 
randomised, sham-controlled, blinded, phase 3 trial
The RIGHT-2 Investigators*
Summary
Background High blood pressure is common in acute stroke and is a predictor of poor outcome; however, large trials of 
lowering blood pressure have given variable results, and the management of high blood pressure in ultra-acute stroke 
remains unclear. We investigated whether transdermal glyceryl trinitrate (GTN; also known as nitroglycerin), a nitric 
oxide donor, might improve outcome when administered very early after stroke onset.
Methods We did a multicentre, paramedic-delivered, ambulance-based, prospective, randomised, sham-controlled, 
blinded-endpoint, phase 3 trial in adults with presumed stroke within 4 h of onset, face-arm-speech-time score of 2 
or 3, and systolic blood pressure 120 mm Hg or higher. Participants were randomly assigned (1:1) to receive 
transdermal GTN (5 mg once daily for 4 days; the GTN group) or a similar sham dressing (the sham group) in UK-
based ambulances by paramedics, with treatment continued in hospital. Paramedics were unmasked to treatment, 
whereas participants were masked. The primary outcome was the 7-level modified Rankin Scale (mRS; a measure of 
functional outcome) at 90 days, assessed by central telephone follow-up with masking to treatment. Analysis was 
hierarchical, first in participants with a confirmed stroke or transient ischaemic attack (cohort 1), and then in all 
participants who were randomly assigned (intention to treat, cohort 2) according to the statistical analysis plan. This 
trial is registered with ISRCTN, number ISRCTN26986053.
Findings Between Oct 22, 2015, and May 23, 2018, 516 paramedics from eight UK ambulance services recruited 
1149 participants (n=568 in the GTN group, n=581 in the sham group). The median time to randomisation was 71 min 
(IQR 45–116). 597 (52%) patients had ischaemic stroke, 145 (13%) had intracerebral haemorrhage, 109 (9%) had 
transient ischaemic attack, and 297 (26%) had a non-stroke mimic at the final diagnosis of the index event. In the GTN 
group, participants’ systolic blood pressure was lowered by 5·8 mm Hg compared with the sham group (p<0·0001), 
and diastolic blood pressure was lowered by 2·6 mm Hg (p=0·0026) at hospital admission. We found no difference in 
mRS between the groups in participants with a final diagnosis of stroke or transient ischaemic stroke (cohort 1): 
3 (IQR 2–5; n=420) in the GTN group versus 3 (2–5; n=408) in the sham group, adjusted common odds ratio for poor 
outcome 1·25 (95% CI 0·97–1·60; p=0·083); we also found no difference in mRS between all patients (cohort 2: 
3 [2–5]; n=544, in the GTN group vs 3 [2–5]; n=558, in the sham group; 1·04 [0·84–1·29]; p=0·69). We found no 
difference in secondary outcomes, death (treatment-related deaths: 36 in the GTN group vs 23 in the sham group 
[p=0·091]), or serious adverse events (188 in the GTN group vs 170 in the sham group [p=0·16]) between treatment 
groups. 
Interpretation Prehospital treatment with transdermal GTN does not seem to improve functional outcome in patients 
with presumed stroke. It is feasible for UK paramedics to obtain consent and treat patients with stroke in the ultra-
acute prehospital setting.
Funding British Heart Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
High blood pressure is common in acute stroke and 
is a predictor of poor outcome; however, large trials 
investigating lowering blood pressure have given variable 
results, and the management of high blood pressure in 
acute stroke remains unclear,1 although lowering blood 
pressure in intracerebral haemorrhage is recom mended 
in hospital.2 Nitric oxide (NO) donors are candi date 
treatments for acute stroke because of their cerebral and 
systemic vasodilatory action, which leads to a reduction in 
blood pressure. Preclinical stroke studies3,4 found that NO 
donors improved regional cerebral blood flow and 
reduced stroke lesion size if administered rapidly. Further, 
vascular NO concentrations are low in acute stroke and 
are associated with a poor outcome,5,6 raising the 
possibility that supplementing NO might be beneficial.
Five randomised trials7–11 of an NO donor, transdermal 
glyceryl trinitrate (GTN; also known as nitroglycerin), 
in acute stroke showed that GTN lowered peripheral 
and central blood pressure, 24 h blood pressure, pulse 
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pressure, and augmentation index. Conversely, GTN had 
no effect on middle cerebral artery blood flow velocity, 
cerebral blood flow, intracranial pressure, or platelet 
function.7–9 Although four of the trials7–9,11 were neutral for 
functional outcome, GTN improved functional outcome in 
the phase 2 Rapid Intervention with Glyceryl trinitrate in 
Hypertensive stroke Trial (RIGHT),10 with random isation 
by paramedics within 4 h of stroke, and in a prespecified 
subgroup analysis of the phase 3 hospital-based Efficacy of 
Nitric Oxide in Stroke trial (ENOS),11,12 with randomisation 
within 6 h of stroke. Summary and individual patient data 
meta-analyses13,14 of these five trials suggested that very 
early administration of GTN within 6 h of onset (n=312) 
was beneficial in both ischaemic stroke and intracerebral 
haemorrhage, and reduced death, disability, cognitive 
impairment, mood disturb ance, and poor quality of life. 
Beyond 6 h, treat ment effects were neutral.
For stroke interventions that do not require previous 
neuroimaging and that might have benefit in both 
ischaemic stroke and intracerebral haemorrhage, treat-
ment before hospital admission will reduce time to 
initiation of treatment. The Field Administration of 
Stroke Therapy-Magnesium (FAST-MAG) ambulance-
based stroke trial15 successfully recruited 1700 patients in 
the USA, but no previous large prehospital stroke trials 
have been completed in the UK.
We did the phase 3 RIGHT-2 trial to assess the safety 
and efficacy of GTN when given very early after presumed 
stroke onset by paramedics before participants were 
admitted to hospital. We also assessed the feasibility of 
performing a large multicentre, ambulance-based, 
paramedic-delivered trial in patients with presumed 
stroke in the UK.
Methods
Study design and participants
RIGHT-2 was a pragmatic, multicentre, paramedic-
delivered, ambulance-based, prospective, randomised, 
sham-controlled, participant-blinded and outcome-
blinded, phase 3 trial in adult participants with ultra-
acute presumed stroke within 4 h of onset in the UK.
Adult patients were eligible for inclusion after an 
emergency telephone call (to 999 UK ambulance services) 
for presumed stroke if they presented within 4 h of onset 
of their symptoms to a trial-trained paramedic from a 
participating ambulance service and could be taken to a 
participating hospital. Patients had to have a face-arm-
speech-time (FAST) score of 2 or 3 (thus ensuring the 
presence of motor weakness), and a systolic blood 
pressure of 120 mm Hg or higher. Patients from a 
nursing home, with reduced consciousness (Glasgow 
Coma Scale [GCS] score, <8 of 15), with hypoglycaemia 
(capillary glucose concentration <2·5 mmol/L), or who 
had a witnessed seizure were excluded (see appendix for 
a complete list of the inclusion and exclusion criteria).
Paramedics managed the primary consent process, and 
patients with capacity gave written informed consent that 
covered the whole trial. If capacity was absent, proxy 
consent was obtained from an accompanying relative, 
carer, or friend, if present, or from the paramedic if no 
accompanying person was present (as done in RIGHT).10 
Confirmatory consent was obtained from the patient, or 
their relative, carer, or friend (if available) in hospital 
when the patient lacked capacity in the ambulance.
The final diagnosis was made after arrival to a 
participating hospital by the principal investigator based 
on clinical and neuroimaging findings and was 
categorised as intracerebral haemorrhage, ischaemic 
stroke, transient ischaemic attack, or non-stroke or 
transient ischaemic attack mimic.
The study was approved by the UK regulator (Medicines 
and Healthcare products Regulatory Agency, reference: 
03057/0064/001–0001; Eudract 2015–000115–40) and 
national research ethics committee (IRAS: 167115) and 
was adopted by the National Institute for Health Research 
Clinical Research Network.
Research in context
Evidence before this study
We searched PubMed, Embase, and Web of Science for 
relevant articles on Sept 12, 2018, using the search terms 
“stroke”, “cerebrovascular accident”, “nitric oxide donor”, 
and “randomised controlled trial”. We also manually searched 
original articles and reviews in our own reference library. 
Searches were restricted to completed trials in humans with 
abstracts or full texts published and relating to administration 
of glyceryl trinitrate (GTN) within 6 h of stroke onset, and in 
which information on functional outcome and death was 
available. When combining results from two randomised 
controlled patient-masked trials with blinded-outcome 
assessment, one a pilot ambulance-based study and the other 
a prespecified subgroup of a large hospital-based trial, 
treatment with GTN within the first 6 h of stroke onset was 
associated with less death and reduced death or dependency, 
both overall and separately in ischaemic stroke and 
intracerebral haemorrhage.
Added value of this study
Ultra-acute administration of GTN in the ambulance within 
4 h of stroke onset did not alter functional outcome in patients 
suspected to have stroke. It was feasible for UK paramedics to 
recruit, obtain consent, and treat patients with stroke in the 
prehospital environment.
Implications of all the available evidence
We did not find evidence that ultra-early administration of 
transdermal GTN improves functional outcome or reduces 
death in patients with suspected ultra-acute stroke. Large 
paramedic-delivered trials are possible in the UK.
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Details of the trial design, statistical analysis plan, and 
baseline data have been published,16–18 and the design and 
protocol are summarised in the appendix. The study 
protocol is available online.
Randomisation and masking
Patients were enrolled and randomly assigned (1:1) by 
paramedics to receive transdermal GTN (5 mg as 
Transiderm-Nitro 5, Novartis, Frimley, UK; the GTN 
group) or a similar-appearing sham skin dressing 
(DuoDERM hydrocolloid dressing, Convatec, Flintshire, 
UK; the sham group). Randomisation was stratified 
by ambulance station with blocks of four packs 
(two active, two control) in a random permuted order. 
Each treat ment pack was sealed to maintain blinding of 
paramedics. Ambulances carried only one pack at a 
time—paramedics signed-out the treatment pack with 
the lowest random isation number from their ambulance 
station at the start of their shift and returned it if unused 
at the end of their shift. Opened but unused packs were 
returned to the coordinating centre. GTN patches or 
sham dressings came in marked sealed sachets so 
paramedics and nurses doing medication rounds in 
hospital knew treatment assignment. However, partici-
pants were effectively masked since the patches and 
dressings themselves were unlabelled, and a gauze 
dressing was taped over the top of the patch or dressing 
to provide additional masking.
Procedures
The first treatment (GTN or sham) was administered by 
the paramedic immediately after randomisation in the 
ambulance, and further treatments were given to the 
patient for up to 3 days while in hospital. Patches or 
dressings were placed on the shoulder or back and the 
site changed daily.
Ambulance data (before and after first treatment) and 
hospital-collected clinical and neuroimaging data at 
admission (after first treatment), day 4 (end of treatment), 
and on death or discharge were entered online into a 
secure web-based database system. These data were then 
validated and used to confirm the patient’s eligibility.
Outcomes
The primary outcome was functional outcome assessed 
with the 7-level modified Rankin Scale (mRS), measured 
at 90 days after randomisation.19 mRS scores range from 
0 to 6, with a score of 0 indicating no symptoms, 
1 indicating some symptoms, 2–5 indicating increasing 
levels of disability and dependency, and 6 indicating 
death. Outcomes were recorded centrally by telephone 
by a trained assessor masked to treatment allocation; 
to ensure reliable scoring, raters used a structured 
questionnaire.20 If the participant could not be contacted 
by telephone (after multiple attempts), a questionnaire 
covering the same outcome measures was sent by post. 
The primary analysis involved a comparison of the 
distribution of all 7 levels of the mRS (shift) between the 
treatment groups.21
Participants were seen at day 4 (or at discharge, if 
earlier) to assess adherence to treatment and neurological 
deterioration (increase in the National Institutes of 
Health Stroke Scale [NIHSS] by at least 4 points from 
hospital admission to day 4 or worsening conscious 
level in the NIHSS consciousness domain item 1a). At 
discharge from hospital, duration of stay and discharge 
destination (to institution or home) were recorded. Pre-
specified secondary outcomes at day 90 included activi-
ties of daily living (Barthel Index), cognition (modified 
telephone Mini-Mental State Examination [t-MMSE], 
Telephone Interview for Cognition Scale-modified 
[TICS-M], categorical verbal fluency [with the use of 
animal naming]), health-related quality of life (European 
Quality of Life-5 dimensions-3 level [EQ-5D-3L], from 
which a health status utility value [HSUV] was calculated, 
EQ-visual analogue scale [EQ-VAS]), and mood 
(abbreviated Zung depression score [ZDS]) were 
recorded—all of which were used in ENOS.11
Safety outcomes included all-cause and cause-specific 
case fatality, hypotension or hypertension occurring 
during the first 4 days (as reported by investigators), and 
serious adverse events (all up to day 5, and fatal from 
day 5). Serious adverse events were validated and 
categorised by expert adjudicators who were masked to 
treatment assignment.
Plain brain scans (CT or MRI) performed on arrival at 
hospital were collected for central adjudication by 
expert neuroradiologists with the use of assessments 
updated from ENOS.11 Depending on local practice, CT 
or MR angiography was also performed and adjudicated 
centrally (see appendix for more information). Imaging 
outcomes on admission to hospital included infarct 
extent (International Stroke Trial-3 score, Alberta 
Stroke Program Early CT score), presence of hyperdense 
artery, haemorrhagic transformation, and mass effect, 
including midline shift for participants with ischaemic 
stroke, haematoma location, size, volume, extension (to 
sub arachnoid spaces or ventricles), and mass effect, 
including midline shift for intracerebral haemorrhage, 
and type and location of mimics. On the next day, a 
research CT or MRI scan was done to assess safety; the 
same factors were assessed as above for ischaemic 
stroke and intracerebral haemorrhage.22
An independent Data Monitoring Committee reviewed 
unblinded data every 6 months and did a formal interim 
analysis midway through the trial (see appendix for 
description of the stopping rules); this analysis was done 
after 714 patients had been recruited and followed up 
at 90 days and the Data Monitoring Committee recom-
mended that the trial should continue.
Statistical analysis
We required a total sample size of 850 participants 
(425 in each group) to detect a shift in mRS with a 
For the study protocol see 
http://right-2.ac.uk/docs/
protocol50
For the online database system 
see https://www-apache.
nottingham.ac.uk/~nszwww/
right-2/live/right-2_login.php
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common odds ratio [OR] of 0·70,17 assuming an overall 
significance level of 5%, 90% power, distribution of mRS 
scores as shown in the appendix,10 3% loss to follow-up, 
mimic and transient ischaemic attack rate of 20%, and 
reduction for baseline covariate adjustment of 20%.23 
During the trial, we noted the non-stroke diagnosis rate 
exceeded 30%. Since this mimic rate would reduce the 
number of participants recruited with a stroke diagnosis, 
and therefore the statistical power in this group, we 
increased the overall sample size from 850 to 1050 to 
maintain the overall effect size and statistical power. 
Further, a decision was made by the Trial Steering 
Committee to do a hierarchical analysis, comprising a 
sequential analysis done in two progressively inclusive 
cohorts based on the final in-hospital diagnosis: 
participants with confirmed stroke or transient 
ischaemic attack (cohort 1, target disease population) 
and stroke, transient ischaemic attack, or non-stroke or 
transient ischaemic attack (mimic)—ie, all patients 
(cohort 2, intention-to-treat [ITT]). Further information 
is given in the appendix.
We assessed the primary outcome using ordinal logistic 
regression with adjustment for age, sex, premorbid mRS, 
FAST score, baseline systolic blood pressure, index event 
(intracerebral haemorrhage, ischaemic stroke, transient 
ischaemic attack, mimic), time to randomisation, and 
reperfusion treatment (thrombectomy, alteplase, none).17 
We tested the assumption of proportional odds using the 
likelihood ratio test. We assessed heterogeneity of the 
treatment effect on the primary outcome in prespecified 
subgroups by adding an interaction term to an adjusted 
ordinal logistic regression model. An unadjusted and 
per-protocol (as defined in the appendix) analysis is 
shown for completeness. We analysed death using 
Kaplan-Meier and adjusted Cox regression models. We 
assessed other outcomes using adjusted binary  logistic 
regression (neuro logical deterioration, headache, hypo-
tension, hyper tension, feeding status, disposition, death 
in hospital), Cox regression (death), ordinal logistic 
regression (mRS, disposition), multiple linear regression 
(NIHSS, length of stay in hospital, t-MMSE, TICS-M, 
animal naming, ZDS, EQ-5D-HSUV, and EQ-VAS) and 
analysis of covariance (blood pressure). We analysed a 
global outcome (com prising ordered categorical or 
continuous data for mRS, Barthel Index, ZDS, TICS-M, 
and EQ-5D-HSUV) using the Wei-Lachin test.24 Partici-
pants who did not receive their assigned treatment, who 
did not adhere to the protocol, or who had a stroke 
mimic were still followed up in full at day 90 and are 
included in the main analyses. We made no adjustments 
for multiplicity of testing since all secondary analyses 
were hypothesis-generating and designed to support the 
primary analysis. We did primary analyses as randomised 
(cohort 2) using observed outcome data only with 
SAS software (version 9.4). In sensitivity analyses, we 
performed a per-protocol analysis, and missing mRS 
data were imputed using multiple regression-based 
imputation.
Role of the funding source
This work was supported by the British Heart Foundation 
[grant number CS/14/4/30972] and sponsored by the 
University of Nottingham. There was no commercial 
support for the trial, and GTN patches and sham 
dressings were sourced by the Pharmacy at Nottingham 
University Hospitals NHS Trust. The funder of the study 
had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The 
corresponding author and two statisticians (PS, LJW) 
had full access to all the data in the study and the 
corresponding author had final responsibility for the 
decision to submit for publication.
Figure 1: Trial profile for cohort 2
Cohort 2 includes all patients (intention-to-treat population). GTN=glyceryl 
trinitrate.
568 in the GTN group 
568 completed ambulance form 
568 completed baseline form 
Adherence to allocated patch
565 any patch
565 first patch
311 first two patches
198 all four patches 
Day 4 form (end of treatment)
22 died
568 completed
134 <3 days
397 3–5 days
26 >5 days
0 missing 
Hospital discharge or death form
77 died
568 completed
0 missing 
Day 90 follow-up (final)
105 died
13 no vital status
568 completed
47 <83 days
273 83–97 days
248 >97 days
0 missing
11 lost to follow-up
12 withdrawn
1 patient refused
581 in the sham group 
1149 patients randomly assigned 
581 completed ambulance form 
581 completed baseline form 
Adherence to allocated patch
580 any patch
580 first patch
320 first two patches
210 all four patches 
Day 4 form (end of treatment)
19 died
581 completed
131 <3 days
407 3–5 days
33 >5 days
0 missing 
Hospital discharge or death form
63 died
580 completed
1 missing 
Day 90 follow-up (final)
98 died
14 no vital status
581 completed
37 <83 days
300 83–97 days
244 >97 days
0 missing
10 lost to follow-up
13 withdrawn
0 patient refused  
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Results
Between Oct 22, 2015, and May 23, 2018 (appendix), 
1149 participants (cohort 2) were enrolled and randomly 
assigned (n=568 to the GTN group; n=581 to the sham 
group; figure 1) by 516 (35%) of 1492 trial-trained 
paramedics based at 184 ambulance stations in eight (62%) 
of 13 ambulance services in England and Wales; these 
participants were taken to 54 hospitals. For logistical 
reasons, screening logs were not kept. All patients gave 
consent in the ambulance, which was obtained from 
603 (53%) patients, 429 (37%) relatives, carers, or friends, 
and 117 (10%) paramedics. Demographic and clinical 
characteristics were similar in the two treatment groups 
across cohort 1 and cohort 2 (table 1). The mean age was 
72·5 years (SD 14·6), women comprised 48% of the 
participants, 60% of participants had a maximum FAST 
score of 3, and 26% had a GCS of less than 14. The final 
diagnosis of the qualifying event was 52% ischaemic 
stroke, 13% intra cerebral haemor rhage, 9% transient 
ischaemic attack, and 26% stroke or transient ischaemic 
attack-mimicking condition. Com mon causes of stroke 
mimics included seizure (n=50 [18%]), migraine (n=49 
[17%]), and functional symp toms (n=41 [14%]). 
The median time from the onset of symptoms to 
randomisation was 71 min (IQR 45–116) and to start of 
study drug 73 min (48–118) . Overall, the study drug was 
received within 30 min of symptom onset in 59 (5%) 
participants, within 60 min in 439 (38%) participants, 
and within 120 min in 865 (75%) participants.
Adherence to the first randomised treatment was 
excellent in both the confirmed stroke or transient 
ischaemic attack group (cohort 1: 849 (>99%) of target 
disease population) and in all participants (cohort 2: 
1145 (>99%) of ITT population; appendix). In the per-
protocol definition of adherence, which required that at 
least the first two doses of treatment were received, only 
571 (67%) of cohort 1 and 631 (55%) of cohort 2 were 
adherent; common reasons for non-adherence were 
a diagnosis of non-stroke, early discharge, a medical 
decision to stop randomised treatment, a procedural error, 
or missing trial medication (appendix). Just 382 (45%) of 
participants with a stroke or transient ischaemic attack 
(cohort 1), and 408 (36%) of participants overall (cohort 2), 
received all 4 days of treatment.
There were 38 protocol violations in the ambulance 
and these mainly comprised inclusion of patients 
beyond 4 h, with a FAST score of less than 2, a systolic 
blood pressure of less than 120 mm Hg, or who were 
from a nursing home (appendix). The most common 
protocol violations in hospital involved not administering 
the second day’s treatment or failure to obtain secondary 
consent.
In cohort 1, systolic blood pressure at baseline was 
163·2 mm Hg (SD 24·7) and diastolic was 91·9 mm Hg 
(18·5; table 1) and reduced in both GTN and sham groups 
over the 4 days after randomisation (appendix). After 
treatment, systolic blood pressure reduced by 5·8 mm Hg 
(p<0·0001) at hospital admission and diastolic by 
2·6 mm Hg (p=0·0026) in the GTN group compared 
with the sham group. At day 2, systolic blood pressure 
reduced by 5·3 mm Hg (p=0·00016) and diastolic by 
2·6 mm Hg (p=0·0054) in the GTN group compared 
with the sham group. The difference in blood pressure 
between the GTN and sham groups then diminished 
with no difference at days 3 and 4. Similar findings were 
seen for the effect of GTN on blood pressure in all 
patients (cohort 2; appendix). In all patients, symptomatic 
hypotension was more common in the GTN group 
(21 [4%] patients) than in the sham group (9 [2%] patients; 
Patients with confirmed 
stroke or transient ischaemic 
attack (cohort 1)* 
All patients (cohort 2)† 
GTN group Sham group GTN group Sham group
Ambulance data (before randomisation)
Number of patients 434 418 568 581
Consent
Participant 220 (51%) 206 (49%) 296 (52%) 307 (53%)
Relative, carer, or friend 169 (39%) 172 (41%) 213 (38%) 216 (37%)
Paramedic 45 (10%) 40 (10%) 59 (10%) 58 (10%)
Age, years 73·7 (12·8) 75·3 (12·3) 72·3 (14·6) 72·7 (14·6)
Sex
Men 234 (54%) 220 (53%) 294 (52%) 300 (52%)
Women 200 (46%) 198 (47%) 274 (48%) 281 (48%)
Time from onset to randomisation, 
min
70 (45–107) 70 (45–110) 70 (45–115) 72 (45–118)
Electrocardiogram, atrial fibrillation 
or flutter
81 (24%) 77 (22%) 92 (21%) 95 (20%)
Systolic blood pressure, mm Hg 163·4 (24·5) 163·0 (24·9) 161·5 (24·7) 162·8 (25·5)
Diastolic blood pressure, mm Hg 92·2 (19·1) 91·5 (17·8) 91·5 (18·5) 91·6 (17·2)
Heart rate, beats per min 81·6 (18·7) 82·2 (18·6) 81·7 (18·0) 82·6 (19·2)
Glasgow Coma Scale <14 123 (28%) 106 (25%) 162 (29%) 140 (24%)
FAST score of 3 276 (64%) 270 (65%) 343 (60%) 347 (60%)
Hospital admission data (after randomisation)
Number of patients 434 418 568 581
Ethnic group, non-white 35 (8%) 43 (10%) 50 (9%) 63 (11%)
Premorbid mRS >2 76 (18%) 68 (16%) 115 (20%) 108 (19%)
Medical history
Hypertension 252 (58%) 249 (60%) 313 (56%) 330 (58%)
Diabetes 82 (19%) 86 (21%) 109 (20%) 118 (21%)
Previous stroke 100 (23%) 87 (21%) 137 (25%) 135 (24%)
Ischaemic heart disease 66 (15%) 72 (17%) 95 (17%) 101 (18%)
Current smoking 63 (18%) 51 (15%) 89 (19%) 79 (17%)
Qualifying event
Ischaemic stroke 302 (70%) 295 (71%) 302 (53%) 295 (51%)
Intracerebral haemorrhage 74 (17%) 71 (17%) 74 (13%) 71 (12%)
Stroke type unknown 1 (<1%) 0 1 (<1%) 0
Transient ischaemic attack 57 (13%) 52 (12%) 57 (10%) 52 (9%)
Non-stroke or transient 
ischaemic attack mimic
·· .. 134 (24%) 163 (28%)
Data are n (%), mean (SD), and median (IQR). GTN=glyceryl trinitrate. FAST=face-arm-speech-time test. mRS=modified 
Rankin Scale. *Target disease population. †Intention-to-treat population.
Table 1: Baseline patient characteristics in the ambulance and at hospital admission
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adjusted OR [aOR] 2·49 [95% CI 1·11–5·57]; p=0·026; 
table 2). Heart rate did not differ between the treatment 
groups (data not shown).
Vital status was available in 1122 (98%) participants and 
mRS in 1102 (96%; figure 1); we found no differential loss 
to follow-up or withdrawals between the treatment groups. 
Masking was maintained with participants unable to 
identify which medication they had received (appendix).
In the target disease population of cohort 1 (confirmed 
stroke and transient ischaemic attack), we found no 
Cohort 1* Cohort 2†
Number of 
patients 
(n=852)
GTN group 
(n=434)
Sham group 
(n=418)
acOR, aOR, aDIM, or 
aHR (95% CI)
p value Number of 
patients 
(n=1149)
GTN group 
(n=568)
Sham group 
(n=581)
acOR, aOR, aDIM, or 
aHR (95% CI)
p value
Day 90 mRS, maximum score 
of 6 (primary outcome)
828 3 (2–5) 3 (2–5) 1·25 (0·97 to 1·60) 0·083 1102 3 (2–5) 3 (2–5) 1·04 (0·84 to 1·29) 0·69
Sensitivity analyses
Unadjusted 828 3 (2–5) 3 (2–5) 1·05 (0·83 to 1·33) 0·70 1102 3 (2–5) 3 (2–5) 0·99 (0·81 to 1·22) 0·96
Mean 828 3·4 (2·0) 3·4 (1·9) 0·14 (–0·07 to 0·36) 0·19 1102 3·2 (2·0) 3·2 (1·9) 0·01 (–0·17 to 0·19) 0·92
mRS >2 828 286 (68%) 282 (69%) 1·11 (0·79 to 1·57) 0·55 1102 358 (66%) 373 (67%) 1·02 (0·76 to 1·38) 0·88
Per protocol 714 3 (2–5) 3 (2–5) 1·22 (0·93 to 1·60) 0·14 959 3 (2–5) 3 (2–5) 1·05 (0·84 to 1·33) 0·65
Imputed 852 3 (2–5) 3 (2–5) 1·23 (0·96 to 1·57) 0·10 1149 3 (2–5) 3 (2–5) 1·05 (0·85 to 1·30) 0·65
Hospital admission
NIHSS, maximum score 
of 42
755 10·5 (7·6) 10·4 (7·7) 0·34 (–0·51 to 1·19) 0·43 931 9·7 (7·6) 9·4 (7·5) 0·14 (–0·61 to 0·89) 0·72
GCS, maximum score of 15 835 13·5 (2·3) 13·8 (2·0) –0·37 (–0·64 to –0·10) 0·0068 1076 13·7 (2·2) 13·9 (1·9) –0·19 (–0·42 to 0·04) 0·10
FAST, maximum score of 3 799 2·3 (0·9) 2·2 (1·0) 0·09 (–0·02 to 0·19) 0·10 985 2·2 (1·0) 2·1 (1·0) 0·03 (–0·07 to 0·13) 0·51
OCSP, TACS 822 161 (38%) 149 (37%) 1·13 (0·82 to 1·55) 0·45 1046 176 (34%) 174 (33%) 1·03 (0·78 to 1·37) 0·83
Day 4 (discharge)
Death 849 20 (5%) 18 (4%) 1·17 (0·57 to 2·39) 0·68 1128 22 (4%) 19 (3%) 1·19 (0·60 to 2·35) 0·63
Neurological 
deterioration‡
534 60 (23%) 56 (21%) 1·14 (0·74 to 1·77) 0·56 586 62 (21%) 59 (20%) 1·08 (0·70 to 1·65) 0·73
Headache§ 843 41 (10%) 28 (7%) 1·41 (0·84 to 2·37) 0·19 1117 49 (9%) 36 (6%) 1·43 (0·90 to 2·27) 0·13
Hypotension§ 844 18 (4%) 9 (2%) 2·07 (0·90 to 4·75) 0·085 1118 21 (4%) 9 (2%) 2·49 (1·11 to 5·57) 0·026
Hypertension§ 844 89 (21%) 93 (22%) 0·82 (0·57 to 1·18) 0·28 1118 106 (19%) 108 (19%) 0·96 (0·69 to 1·33) 0·81
Feeding: non-oral 806 123 (30%) 132 (33%) 0·89 (0·63 to 1·26) 0·51 1049 130 (25%) 139 (26%) 0·89 (0·65 to 1·24) 0·50
Events in hospital
Length of stay 847 17·4 (29·7) 19·1 (28·9) –1·35 (–5·16 to 2·46) 0·49 1126 14·6 (27·0) 15·3 (25·7) –1·09 (–4·00 to 1·81) 0·46
Died 847 72 (17%) 60 (14%) 1·28 (0·84 to 1·96) 0·26 1126 78 (14%) 63 (11%) 1·35 (0·90 to 2·02) 0·15
Died or in an institution 831 180 (42%) 167 (41%) 1·17 (0·84 to 1·61) 0·35 1102 193 (35%) 186 (33%) 1·08 (0·81 to 1·46) 0·60
Day 90
Death 841 97 (23%) 79 (19%) 1·24 (0·91 to 1·68) 0·17 1122 105 (19%) 98 (17%) 1·11 (0·84 to 1·47) 0·47
Disposition, maximum 
score of 3¶
809 1 (1–2) 1 (1–2) 1·32 (0·96 to 1·82) 0·086 1069 1 (1–2) 1 (1–2) 1·11 (0·83 to 1·47) 0·48
EQ-5D-HSUV, maximum 
score of 1||
798 0·4 (0·4) 0·4 (0·4) –0·02 (–0·07 to 0·03) 0·42 1055 0·4 (0·4) 0·4 (0·4) 0·00 (–0·04 to 0·05) 0·95
Barthel Index, maximum 
score of 100d
795 56·2 (45·0) 57·5 (43·9) –2·74 (–7·82 to 2·33) 0·29 1048 60·3 (43·7) 61·3 (43·1) –0·24 (–4·54 to 4·06) 0·91
TICS-M, maximum score 
of 39 ||**
439 12·4 (12·3) 13·2 (12·1) –0·87 (–2·63 to 0·90) 0·34 551 13·5 (12·3) 13·7 (11·8) 0·06 (–1·50 to 1·63) 0·94
ZDS, maximum score of 
100||**
499 67·3 (29·7) 66·0 (29·1) 1·38 (–2·87 to 5·63) 0·52 638 66·5 (28·8) 65·1 (28·6) 0·53 (–3·22 to 4·28) 0·78
Global outcome (MWD) 828 ·· ·· 0·02 (–0·06 to 0·10) 0·62 1102 ·· ·· 0·00 (–0·06 to 0·07) 0·92
Home time, days‡ 682 55·8 (49·2) 55·5 (46·8) –0·30 (–6·14 to 5·54) 0·92 903 63·5 (48·9) 63·7 (46·9) 2·18 (–2·81 to 7·16) 0·39
Data are n (%), mean (SD), and median (IQR), unless otherwise stated. GTN=glyceryl trinitrate. acOR=adjusted common odds ratio. aOR=adjusted odds ratio. aDIM=adjusted difference in means. aHR=adjusted 
hazard ratio. mRS=modified Rankin scale. NIHSS=National Institutes of Health Stroke Scale. GSC=Glasgow Coma Scale. FAST=face-arm-speech-time test (calculated from NIHSS). OCSP=Oxford Community Stroke 
Project. TACS=total anterior circulation syndrome (in ischaemic stroke and intracerebral haemorrhage). EQ-5D-HSUV=Euro-Quality of life-5 Dimensions health status utility value. TICS-M=modified telephone 
interview cognition scale. ZDS=Zung depression scale. MWD=Mann-Whitney difference. EQ-VAS=Euro-Quality of life-Visual Analogue Scale. t-MMSE=telephone mini-mental state examination. *Patients with 
confirmed stroke or transient ischaemic attack (modified intention-to-treat population). †All patients (intention-to-treat population). ‡Neurological deterioration from hospital admission: NIHSS ≥4 points or 
≥2 point increase in any domain. §Clinical. ¶Disposition: home (score of 1), institution or in hospital (score of 2), died (score of 3) by day 90. ||Death scored as: Barthel Index –5, verbal fluency (animal naming) –1, 
EQ-VAS –1, home time –1, t-MMSE –1, TICS-M –1, EQ-5D-HSUV 0, GCS 2, mRS 6, NIHSS 43, ZDS 102·5. **Incomplete TICS-M and ZDS due to inability by participants with severe stroke to respond to questions.
Table 2: Primary and secondary outcomes at day 4 and day 90 in cohort 1 and cohort 2
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strong evidence of an effect of GTN on functional 
outcome at 90 days compared with sham (mRS 3 
[IQR 2–5] in the GTN group vs 3 [2–5] in the sham 
group; adjusted common OR [acOR] 1·25 [95 % CI 
0·97–1·60]; p=0·083; table 2; figure 2), and the acOR of 
1·25 suggests a tendency in favour of sham treatment. 
In sensitivity analyses, no difference was found in mRS 
when compared as mean difference, proportions with 
poor outcome (mRS >2), mRS in the per-protocol 
population, or when data were imputed for participants 
without a recorded mRS at day 90 (table 2). A significant 
interaction of the effect of GTN on mRS was present 
for time to randomisation, with a negative effect of 
GTN apparent in participants recruited within 1 h of 
symptom onset (figure 3); no other significant effect 
modification by subgroups was detected. Post-hoc 
assessment of the treatment effect on mRS in clinically 
relevant subgroups defined on or after admission to 
hospital (ie, potentially affected by treatment) showed a 
significant interaction with a worse outcome in patients 
with a more severe stroke on admission to hospital 
(post-treatment NIHSS >12; appendix).
When assessed in the target disease population 
(cohort 1), mRS did not differ between GTN and sham 
groups in participants with stroke (3 [IQR 2–6] in the 
GTN group vs 3 [2–5] in the sham group; acOR 1·26 
[95% CI 0·96–1·64]; p=0·095; n=722), ischaemic stroke 
(3 [2–5] in GTN and sham groups; 1·15 [0·85–1·54]; 
p=0·36; n=580), or transient ischaemic attack (3 [1–3] in 
the GTN group vs 2 [1–3] in the sham group; 1·57 
[0·74–3·35]; p=0·24; n=105). However, GTN was as-
sociated with a non-significantly worse outcome in 
patients with a final diagnosis of intracerebral haemor-
rhage (5 [4–6] in the GTN group vs 5 [3–5] in the sham 
group; 1·87 [0·98–3·57]; p=0·057; n=142; appendix).
Analysis of the ITT population (cohort 2) also showed 
that mRS did not differ between GTN and sham groups 
in the primary analysis (3 [IQR 2–5] for both groups; 
acOR 1·04 [95% CI 0·84–1·29]; p=0·69; table 2; appendix) 
or in any sensitivity analysis (data not shown). In 
predefined subgroups, a significant interaction was seen 
by final diagnosis (appendix); in contrast to the effect of 
GTN in stroke or transient ischaemic attack (see above), 
GTN appeared to be associated with an improved mRS in 
patients with a mimic (non-stroke or transient ischaemic 
attack mimic; 3 [1–4] for both groups; 0·54 [0·34–0·85]; 
p=0·0081); in a post-hoc analysis, this positive finding 
was not localised to any particular type of mimic (data 
not shown).
GCS at admission to hospital was 0·4 points lower in 
the GTN group. Because of this difference, we performed 
a post-hoc sensitivity analysis adding baseline GCS to the 
statistical model for the primary outcome in cohort 1, 
which had minimal effect on the result (OR 1·22 [95% CI 
0·95–1·56]). Otherwise, we found no evidence of any 
other differences between GTN and sham groups in 
secondary outcomes in cohort 1 (table 2; appendix). 
A global analysis encompassing the primary outcome 
and prespecified secondary outcomes showed no 
difference (table 2; appendix).
Compared with the sham group, patients with an 
ischaemic stroke in the GTN group were less likely to have 
thrombectomy (appendix); conversely, patients in the GTN 
group were more likely to be ventilated in an intensive care 
unit. Use of other standard stroke treatments did not differ 
between the randomised treatment groups. No differences 
were found between GTN and sham groups in secondary 
outcomes at day 90 (table 2).
The proportion of deaths at day 4 did not differ between 
GTN and sham groups either in the target disease 
population (cohort 1) or in the full ITT population 
(cohort 2; table 2). Similarly, the proportion of deaths by 
day 90 did not differ between groups in cohort 1 (adjusted 
HR [aHR] 1·24 [95% CI 0·91–1·68]; p=0·17; table 2; 
appendix) or in cohort 2. The most common causes of 
death were progression or recurrence of the index stroke 
and pneumonia. A slight excess of headaches by day 4 
was apparent in the GTN group. The number of 
participants experiencing one or more serious adverse 
events did not differ between the GTN and sham groups 
(188 [33%] patients vs 170 [29%]; p=0·16; appendix) 
although cardiovascular serious adverse events were 
more common in the GTN group (29% [5%] vs 16 [3%]). 
No suspected unexpected serious adverse reactions 
occurred.
The on-treatment hospital-based imaging findings for 
participants with a final diagnosis of stroke or transient 
ischaemic attack are shown in the appendix. In 
ischaemic stroke, scanning was done on admission at 
2·2 h and on day 2 at 27·7 h after onset of stroke or 
transient ischaemic attack. No differences were found 
between GTN and sham groups in respect of infarct 
size, swelling, or mass effect on plain brain CT. 
Patients receiving intravenous thrombolysis were non-
significantly less likely to have haemorrhagic trans-
formation with GTN than with sham (5 [3%] vs 11 [8%]; 
OR 0·38 [95% CI 0·13–1·13]; p=0·082). For participants 
with intracerebral haemorrhage, scan ning was done on 
admission at an average of 2·3 h and 28·9 h after onset 
Figure 2: Distribution of mRS score at day 90 for GTN versus sham in cohort 1
Cohort 1 includes patients with confirmed stroke or transient ischaemic stroke 
(modified intention to treat). Comparison by ordinal logistic regression adjusted 
for age, sex, premorbid mRS, FAST score, pretreatment systolic blood pressure, 
index event (intracerebral haemorrhage, ischaemic stroke, transient ischaemic 
attack, mimic), and time to randomisation. GTN=glyceryl trinitrate. 
mRS=modified Rankin Scale. FAST=face-arm-speech-time test. 
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of stroke or transient ischaemic attack (appendix). GTN 
was associated with larger haematoma than sham 
(1·95 [1·07–3·58]; p=0·030) and more mass effect 
(2·42 [1·26–4·68]; p=0·0083) at hospital admission.
Addition of the results for participants with confirmed 
stroke or transient ischaemic attack in cohort 1 (target 
disease population) in RIGHT-2 to the positive published 
Cochrane review14 for hyperacute administration of 
GTN, resulted in neutral effects for end-of-trial death or 
dependency (mRS >2; OR 0·80 [95% CI 0·59–1·10]; 
p=0·17; heterogeneity I²=16%; p=0·30) and death (0·52 
[0·16–1·72]; p=0·28; I²=86%; p=0·0007; appendix). 
Heterogeneity between trial results was apparent for 
death, emphasising the difference between the results 
for RIGHT-2 versus the earlier RIGHT10 and ENOS-
early11,12 trials. 
Figure 3: Effect of GTN versus sham on mRS score at day 90 in cohort 1 prespecified subgroups defined before treatment and admission to hospital
Comparison by ordinal logistic regression adjusted for age, sex, premorbid mRS, FAST, pretreatment systolic blood pressure, index event (intracerebral haemorrhage, 
ischaemic stroke, transient ischaemic attack, mimic), time to randomisation, and reperfusion therapy (alteplase, intra-arterial therapy, none). GTN=glyceryl trinitrate. 
mRS=modified Rankin Scale. FAST=face-arm-speech-time test.
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Discussion
RIGHT-2 recruited 1149 patients who were taken to 
54 hospitals; 516 paramedics from 184 ambulance 
stations within eight UK ambulance services performed 
screening, obtained consent, and delivered treatment 
and early follow-up measurement. Consent or proxy 
consent was obtained from patients, relatives, carers, or 
friends of the patient, or by the recruiting paramedic. 
Treatment was commenced very early, and faster than in 
hospital-based trials, with 38% of patients treated 
in the first 60 min after stroke onset (the so-called 
golden hour).25 Hence, we have shown that it is feasible 
to perform a large multicentre, paramedic-delivered, 
ambulance-based trial in patients with suspected stroke 
in the UK. Having shown feasibility, we compared the 
effect of GTN with sham and found that treatment with 
GTN did not affect functional outcome in patients with 
the target diagnosis of confirmed stroke or transient 
ischaemic attack or in the overall recruited population.
The results shown for GTN differ from those reported 
in a previous small phase 2, ambulance-based trial 
(RIGHT,10 with recruitment <4 h of onset) and a subgroup 
of a large phase 3 trial (ENOS,12 recruitment <6 h of 
onset). These discrepant results have several potential 
explanations. First, GTN might simply be ineffective in 
very early stroke, as suggested by the absence of any 
effect of GTN on multiple secondary outcomes and a 
global outcome and by neutral meta-analyses when 
combining ENOS-early, RIGHT, and RIGHT-2. Second, 
the discrepant findings might be due to chance rather 
than any true positive or negative effect of GTN. Chance 
could also account for the observation that GTN appeared 
to be beneficial in participants with a final diagnosis of 
non-stroke or transient ischaemic attack mimic 
irrespective of the underlying mimic diagnosis. Third, 
the difference between RIGHT-2 and ENOS-early or 
RIGHT might be real, due to intrinsic differences in 
their design: in RIGHT-2, we randomly assigned patients 
far earlier (median 71 min) than in RIGHT and ENOS-
early combined (median 257 min) and so will have 
recruited a different cohort of patients. Compared with 
these earlier trials, participants in RIGHT-2 were older 
and more likely to have premorbid dependency, diabetes, 
previous stroke, and ischaemic heart disease; and, among 
the patients with intracerebral haemorrhage, they were 
more likely to still be in a period of haematoma 
expansion. All these factors might have contributed to 
different effects of GTN on functional outcome, as was 
apparent for reductions in systolic blood pressure 
(6·2 mm Hg in RIGHT-2 vs 9·4 mm Hg in ENOS-
early).11,12 Finally, studies showing a positive effect of GTN 
within 6 h used a 7-day treatment period and had higher 
rates of adherence, so it is conceivable that GTN was not 
given for long enough in RIGHT-2.
Although RIGHT-2 was a neutral trial, GTN was 
associated with a tendency for a worse functional outcome 
in patients with confirmed stroke or transient ischaemic 
attack (cohort 1), with a 95% CI covering a range from a 
clinically insignificant benefit (OR 0·97) to a clinically 
significant hazard (OR 1·60). This tendency towards 
harm was particularly seen in patients with intracerebral 
haemorrhage, very early stroke (<1 h), and severe stroke 
(GCS <12, NIHSS >12). Further, the imaging findings 
support a negative effect of GTN in ultra-acute intra-
cerebral haemorrhage with larger haematoma, and more 
haematoma expansion, peri haematoma oedema, mass 
effect, and midline shift. There are several explanations 
for the potential hazard in intracerebral haemorrhage, 
which has a higher base rate of ultra-early neurological 
deterioration than ischaemic stroke,26 and these are given 
in decreasing order of likelihood. First, the earliest stage 
in haemostasis is vasoconstriction and GTN might 
prevent this protective response and so lead to very early 
haematoma expansion. Second, although we did not 
identify antiplatelet effects with GTN in a previous study 
of patients with stroke,7 others have reported this response 
in laboratory experiments,27 and GTN could therefore 
have amplified haematoma expansion in intracerebral 
haemorrhage thereby countering any effects of lowering 
blood pressure. Third, venodilators, such as sodium 
nitroprusside and GTN, have been shown experimentally 
and clinically to raise intracerebral pressure and reduce 
cerebral blood flow, particularly if intracerebral pressure 
is already elevated.28,29 Reduced blood flow might then 
induce peri-haematoma ischaemia. Although pilot work 
did not find a negative effect of GTN on cerebral blood 
flow or cerebral perfusion pressure in patients in hospital 
with recent stroke,8,9,30 these studies were not in the ultra-
acute period after stroke and were mainly in ischaemic 
stroke, and so they might not be directly relevant to 
the RIGHT-2 population. Last, GTN can stimulate the 
formation of reactive oxygen species such as superoxide 
(O2–) and peroxynitrite (OONO–), which might attenuate 
vasodilation and increase the potential for cellular 
damage.31
Preclinical studies of neuroprotective and collateral 
enhancement therapy in ischaemic stroke suggest that 
treatment is most effective when administered rapidly 
after symptom onset. Ideally treatment would be started 
before hospital admission to reduce stroke-to-needle 
time.32 The US FAST-MAG trial15 successfully randomly 
assigned 1700 participants in ambulances to receive 
intravenous magnesium or placebo within 2 h of 
symptom start and took them to 36 hospitals. RIGHT-2 
extends these observations showing that a large stroke 
ambulance trial can be performed embedded in the UK 
national health service involving multiple ambulance 
services and hospitals. Hence, other interventions that 
do not require previous CT scanning could be tested in 
this environment in the future. By extrapolation, para-
medics will also be able to administer such interventions 
routinely in the ambulance once they have been shown 
to be effective in one or more types of stroke and safe 
in mimics.
Articles
1018 www.thelancet.com   Vol 393   March 9, 2019
The present trial has several strengths, including the 
large sample size, generalisability due to wide inclusion 
criteria, central concealment of treatment assignment, 
excellent adherence to the first dose of allocated treat-
ment, prospective collection of multiple functional 
outcomes and safety measures such as hypotension and 
hypertension, near-complete follow-up (96% of patients 
had their primary outcome recorded), and central 
masked assessment of outcomes at day 90. Patients 
received modern care, including stroke unit admission, 
thrombolysis, thrombectomy, and hemicraniectomy.
Several limitations are also present. First, GTN was 
administered in a single-blind design since no com-
mercial sources of placebo patches are available. Despite 
this design, patient-blinding at day 90 was successful 
through use of a near identical sham patch, and both 
GTN and sham patches were unmarked; placement of a 
gauze dressing over the patch8,9,10 gave additional 
blinding. Further, outcomes measured at day 90 were 
assessed centrally by trained staff masked to treatment 
assignment who were not involved in hospital care of 
enrolled patients. Second, many patients did not receive 
randomised treatment for the intended minimum period 
of 2 days, and even fewer for the full 4 days; hence, 
participants might have received inadequate treatment. 
Third, the difference in blood pressure between GTN 
and sham was small and less than that seen in the large 
ENOS trial.11,12 Although this difference might reflect 
inaccuracies in blood pressure measurement in the 
emergency environment of an ambulance and hospital 
admission, it might also explain the lack of benefit in 
ischaemic stroke. Fourth, we had to increase the sample 
size, an unplanned change that was necessary because of 
the unexpectedly high mimic rate. Last, the trial’s wide 
inclusion criteria recruited a population of patients with 
stroke that would not normally enter hospital-based 
trials. In this respect, a group of participants with very 
severe intracerebral haemorrhage were enrolled who 
deteriorated rapidly and then died, which could have 
neutralised any treatment effect.
As far we are aware, RIGHT-2 is the first acute stroke 
trial to use a hierarchical approach to analysis in which 
the first analysis in the primary family was performed in 
the target population, with the potential for a subsequent 
primary analysis across the entire ITT population. We 
followed this predefined plan17 since the high mimic rate 
had the potential to dilute any treatment effect. Although 
the non-positive result in the target population precluded 
testing the ITT population, this approach had the 
advantage that the primary analysis of the study directly 
addressed the core question of the biological benefit of 
drug administration in patients with the disease of 
interest.
In summary, treatment with transdermal GTN 
administered before hospital did not alter functional 
outcome in participants with ultra-acute stroke. The 
signals of potential adverse effect of GTN in intracerebral 
haemorrhage are not definitive, but suggest the advisability 
of close safety monitoring in ongoing trials of prehospital 
GTN in ultra-acute stroke (ISRCTN99503308). Never-
theless, earlier findings in the large ENOS trial, including 
in intracerebral haemorrhage, suggest that transdermal 
GTN is safe when administered later in hospital11 and 
might continue to be used for lowering blood pressure, for 
example before thrombolysis. Finally, the study shows that 
large ambulance-based studies are feasible in the UK and, 
by extrapolation and taking into account the FAST-MAG 
trial,15 in most developed countries.
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